MONTREAL, Sept. 03, 2026 (GLOBE NEWSWIRE) — Pendopharm, a division of Pharmascience Inc., in collaboration with Ascendis Pharma A/S, today announced that Canada’s Drug Agency, or CDA-AMC, has recommended that Yorvipath® (palopegteriparatide injection) be reimbursed with conditions by participating public drug plans for eligible adults with chronic hypoparathyroidism that are not adequately controlled with conventional therapy.






